Goldman Sachs Group Inc Regulus Therapeutics Inc. Transaction History
Goldman Sachs Group Inc
- $613 Billion
- Q4 2024
A detailed history of Goldman Sachs Group Inc transactions in Regulus Therapeutics Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 212,379 shares of RGLS stock, worth $305,825. This represents 0.0% of its overall portfolio holdings.
Number of Shares
212,379
Previous 179,005
18.64%
Holding current value
$305,825
Previous $281,000
19.22%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding RGLS
# of Institutions
70Shares Held
53.5MCall Options Held
13.7KPut Options Held
7K-
Federated Hermes, Inc. Pittsburgh, PA12.9MShares$18.5 Million0.05% of portfolio
-
Nea Management Company, LLC Timonium, MD6.47MShares$9.31 Million0.73% of portfolio
-
Vivo Capital, LLC Palo Alto, CA5MShares$7.2 Million1.54% of portfolio
-
Octagon Capital Advisors LP New York, NY4.85MShares$6.98 Million1.71% of portfolio
-
Black Rock Inc. New York, NY3.97MShares$5.72 Million0.0% of portfolio
About Regulus Therapeutics Inc.
- Ticker RGLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 14,634,400
- Market Cap $21.1M
- Description
- Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-thre...